Effect of raloxifene-analog (LY 117018-Hcl) on the bone marrow of ovariectomized mice.
The effects of LY117018-Hcl (Ralox-A) on body metabolism and differentiation of bone marrow cells were studied in ovariectomized (OVX) mice. We used a mouse model in which estrogen depletion was established for a period of three months before treatment. After that period the animals were divided into three experimental groups consisting of sham-operated, OVX, and OVX-Ralox-A-treated mice. The OVX animals received daily treatment of Ralox-A during two time periods (35 and 65 days). After the treatment we measured the serum levels of protein, ion(s), lipid content, liver, and kidney functions. Our findings indicated that a change in hormonal state did not affect basic body metabolism except for causing an increase in triglycerides (TG) in the OVX mice, which was lowered by the Ralox-A. A higher alkaline phosphatase (ALK-P) level was observed in serum of the OVX-Ralox-A-treated mice than in serum of the OVX mice. We investigated the effects of estrogen depletion on the differentiation of hematopoietic and stromal cells that directly affect bone resorption and formation. OVX and OVX-treated mice were compared with the sham group and assessed for the alteration of these cells' differentiation. The proliferation of stromal stem cells was measured by CFU-F assay in vitro. A decrease in CFU-F colonies derived from OVX mice was observed and after the Ralox-A treatment the number of CFU-F reached sham levels. On the contrary, an upregulation of myeloid cells was observed when analyzed by FACS and by granulocyte/macrophage-colony forming unit (G/M-CFU) assay in selective culture conditions. The G/M-CFUs were increased in the OVX mice and were reduced to sham levels after Ralox-A treatment. In this study, we demonstrated cellular changes of stromal and hemopoietic cells in OVX mice and a beneficial Ralox-A effect that protected such cellular changes.